Literature DB >> 23402998

Distinct renal pathology and a chemotactic phenotype after enterohemorrhagic Escherichia coli shiga toxins in non-human primate models of hemolytic uremic syndrome.

Deborah J Stearns-Kurosawa1, Sun-Young Oh, Rama P Cherla, Moo-Seung Lee, Vernon L Tesh, James Papin, Joel Henderson, Shinichiro Kurosawa.   

Abstract

Enterohemorrhagic Escherichia coli cause approximately 1.5 million infections globally with 176,000 cases occurring in the United States annually from ingesting contaminated food, most frequently E. coli O157:H7 in ground beef or fresh produce. In severe cases, the painful prodromal hemorrhagic colitis is complicated by potentially lethal hemolytic uremic syndrome (HUS), particularly in children. Bacterial Shiga-like toxins (Stx1, Stx2) are primarily responsible for HUS and the kidney and neurologic damage that ensue. Small animal models are hampered by the inability to reproduce HUS with thrombotic microangiopathy, hemolytic anemia, and acute kidney injury. Earlier, we showed that nonhuman primates (Papio) recapitulated clinical HUS after Stx challenge and that novel therapeutic intervention rescued the animals. Here, we present detailed light and electron microscopic pathology examination of the kidneys from these Stx studies. Stx1 challenge resulted in more severe glomerular endothelial injury, whereas the glomerular injury after Stx2 also included prominent mesangiolysis and an eosinophilic inflammatory infiltration. Both toxins induced glomerular platelet-rich thrombi, interstitial hemorrhage, and tubular injury. Analysis of kidney and other organs for inflammation biomarkers showed a striking chemotactic profile, with extremely high mRNA levels for IL-8, monocyte chemoattractant protein 1, and macrophage inflammatory protein 1α and elevated urine chemokines at 48 hours after challenge. These observations give unique insight into the pathologic consequences of each toxin in a near human setting and present potential pathways for therapeutic intervention.
Copyright © 2013 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23402998      PMCID: PMC3620421          DOI: 10.1016/j.ajpath.2012.12.026

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  56 in total

Review 1.  Endothelial dysfunction as a potential contributor in diabetic nephropathy.

Authors:  Takahiko Nakagawa; Katsuyuki Tanabe; Byron P Croker; Richard J Johnson; Maria B Grant; Tomoki Kosugi; Qiuhong Li
Journal:  Nat Rev Nephrol       Date:  2010-11-02       Impact factor: 28.314

2.  Sepsis and pathophysiology of anthrax in a nonhuman primate model.

Authors:  Deborah J Stearns-Kurosawa; Florea Lupu; Fletcher B Taylor; Gary Kinasewitz; Shinichiro Kurosawa
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

3.  Generation of a specific-pathogen-free baboon colony.

Authors:  Roman F Wolf; Richard Eberle; Gary L White
Journal:  J Am Assoc Lab Anim Sci       Date:  2010-11       Impact factor: 1.232

4.  Intracellular targeting of the endoplasmic reticulum/nuclear envelope by retrograde transport may determine cell hypersensitivity to verotoxin via globotriaosyl ceramide fatty acid isoform traffic.

Authors:  S Arab; C A Lingwood
Journal:  J Cell Physiol       Date:  1998-12       Impact factor: 6.384

5.  Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement.

Authors:  Robert A F de Lind van Wijngaarden; Herbert A Hauer; Ron Wolterbeek; David R W Jayne; Gill Gaskin; Niels Rasmussen; Laure-Hélène Noël; Franco Ferrario; Rüdiger Waldherr; E Christiaan Hagen; Jan A Bruijn; Ingeborg M Bajema
Journal:  J Am Soc Nephrol       Date:  2006-07-06       Impact factor: 10.121

Review 6.  Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome.

Authors:  Phillip I Tarr; Carrie A Gordon; Wayne L Chandler
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

7.  Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans.

Authors:  P Boerlin; S A McEwen; F Boerlin-Petzold; J B Wilson; R P Johnson; C L Gyles
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

8.  Glycosphingolipid receptor function is modified by fatty acid content. Verotoxin 1 and verotoxin 2c preferentially recognize different globotriaosyl ceramide fatty acid homologues.

Authors:  A Kiarash; B Boyd; C A Lingwood
Journal:  J Biol Chem       Date:  1994-04-15       Impact factor: 5.157

9.  Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study.

Authors:  Angela Gerber; Helge Karch; Franz Allerberger; Hege M Verweyen; Lothar B Zimmerhackl
Journal:  J Infect Dis       Date:  2002-08-02       Impact factor: 5.226

10.  Kinetic analysis of binding between Shiga toxin and receptor glycolipid Gb3Cer by surface plasmon resonance.

Authors:  H Nakajima; N Kiyokawa; Y U Katagiri; T Taguchi; T Suzuki; T Sekino; K Mimori; T Ebata; M Saito; H Nakao; T Takeda; J Fujimoto
Journal:  J Biol Chem       Date:  2001-09-13       Impact factor: 5.157

View more
  18 in total

1.  Effects of Shiga toxin type 2 on a bioengineered three-dimensional model of human renal tissue.

Authors:  Teresa M DesRochers; Erica Palma Kimmerling; Dakshina M Jandhyala; Wassim El-Jouni; Jing Zhou; Cheleste M Thorpe; John M Leong; David L Kaplan
Journal:  Infect Immun       Date:  2014-10-13       Impact factor: 3.441

Review 2.  Shiga toxins expressed by human pathogenic bacteria induce immune responses in host cells.

Authors:  Moo-Seung Lee; Myung Hee Kim; Vernon L Tesh
Journal:  J Microbiol       Date:  2013-12-19       Impact factor: 3.422

3.  Dextran Sulfate Sodium Colitis Facilitates Colonization with Shiga Toxin-Producing Escherichia coli: a Novel Murine Model for the Study of Shiga Toxicosis.

Authors:  Gregory Hall; Shinichiro Kurosawa; D J Stearns-Kurosawa
Journal:  Infect Immun       Date:  2018-10-25       Impact factor: 3.441

Review 4.  Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS).

Authors:  Ramon Alfonso Exeni; Romina Jimena Fernandez-Brando; Adriana Patricia Santiago; Gabriela Alejandra Fiorentino; Andrea Mariana Exeni; Maria Victoria Ramos; Marina Sandra Palermo
Journal:  Pediatr Nephrol       Date:  2018-01-25       Impact factor: 3.714

5.  Quiescent complement in nonhuman primates during E coli Shiga toxin-induced hemolytic uremic syndrome and thrombotic microangiopathy.

Authors:  Benjamin C Lee; Chad L Mayer; Caitlin S Leibowitz; D J Stearns-Kurosawa; Shinichiro Kurosawa
Journal:  Blood       Date:  2013-06-03       Impact factor: 22.113

Review 6.  Complement, thrombotic microangiopathy and disseminated intravascular coagulation.

Authors:  Shinichiro Kurosawa; Deborah J Stearns-Kurosawa
Journal:  J Intensive Care       Date:  2014-12-31

7.  Pro-Coagulant Endothelial Dysfunction Results from EHEC Shiga Toxins and Host Damage-Associated Molecular Patterns.

Authors:  Chad L Mayer; Caitlin S L Parello; Benjamin C Lee; Kiyoshi Itagaki; Shinichiro Kurosawa; Deborah J Stearns-Kurosawa
Journal:  Front Immunol       Date:  2015-04-07       Impact factor: 7.561

Review 8.  Do the A subunits contribute to the differences in the toxicity of Shiga toxin 1 and Shiga toxin 2?

Authors:  Debaleena Basu; Nilgun E Tumer
Journal:  Toxins (Basel)       Date:  2015-04-29       Impact factor: 4.546

9.  Direct acute tubular damage contributes to Shigatoxin-mediated kidney failure.

Authors:  Stefan Porubsky; Giuseppina Federico; Johannes Müthing; Richard Jennemann; Norbert Gretz; Stefan Büttner; Nicholas Obermüller; Oliver Jung; Ingeborg A Hauser; Elisabeth Gröne; Helmut Geiger; Hermann-Josef Gröne; Christoph Betz
Journal:  J Pathol       Date:  2014-07-25       Impact factor: 7.996

Review 10.  Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals.

Authors:  Chad L Mayer; Caitlin S Leibowitz; Shinichiro Kurosawa; Deborah J Stearns-Kurosawa
Journal:  Toxins (Basel)       Date:  2012-11-08       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.